Limited Edition Golden Llama is here! Check out how you can get one.
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!
Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers !
Shipping Price Reduction for EU Regions
Cat . Non | Espèces | Description du produit | Structure | Pureté | Caractéristique |
---|---|---|---|---|---|
CDA-C82E7 | Cynomolgus | Biotinylated Cynomolgus CD8 alpha / CD8A Protein, His,Avitag™ (MALS verified) | ![]() |
![]() ![]() |
|
CDA-C52H4 | Cynomolgus | Cynomolgus CD8 alpha / CD8A Protein, His Tag (MALS verified) | ![]() |
![]() ![]() |
|
CDA-H52H3 | Human | Human CD8 alpha / CD8A Protein, His Tag (MALS verified) | ![]() |
![]() ![]() |
|
CDA-H82E3 | Human | Biotinylated Human CD8 alpha / CD8A Protein, His,Avitag™ | ![]() |
![]() ![]() |
|
CDA-M82E8 | Mouse | Biotinylated Mouse CD8 alpha / CD8A Protein, His,Avitag™ | ![]() |
![]() ![]() |
Immobilized Cynomolgus CD8 alpha Protein, His Tag (Cat. No. CDA-C52H4) at 5 μg/mL (100 μL/well) can bind Anti-CD8 alpha Antibody, Human IgG1 with a linear range of 0.1-8 ng/mL (QC tested).
The purity of Biotinylated Cynomolgus CD8 alpha Protein, His,Avitag (Cat. No. CDA-C82E7) is more than 90% and the molecular weight of this protein is around 50-60 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
GRANITE | GRANITE-001; GRT-C901/GRT-R902 | Phase 3 Clinical | Bristol-Myers Squibb Company, Gritstone Bio Inc | Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Colonic Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
89Zr-Df-crefmirlimab | IAB-22-M2C | Phase 3 Clinical | Imaginab Inc | Solid tumours; Carcinoma, Merkel Cell; Carcinoma, Renal Cell; Multiple Sclerosis; Lymphoma; Leukoencephalopathy, Progressive Multifocal; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
RB-0003 | RB-0003; BNT-111 | Phase 2 Clinical | Biontech Se, Tron | Melanoma | Details |
GEN-009 | GEN-009 | Phase 2 Clinical | Genocea Biosciences Inc | Skin Melanoma; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung | Details |
VE-800 | VE-800 | Phase 2 Clinical | Vedanta Biosciences Inc | Esophageal Neoplasms; Stomach Neoplasms; Colorectal Neoplasms; Adenocarcinoma; Melanoma; Neoplasm Metastasis | Details |
EBViNT Cell (Eutilex) | Phase 2 Clinical | Eutilex | Lymphoma, Extranodal NK-T-Cell | Details | |
ZED88082A | ZED88082A | Phase 2 Clinical | Umcg The University Medical Center Groningen | Neoplasms; Neoplasm Metastasis | Details |
NY-ESO-1-specific autologous CD8+ T-cell therapy (Fred Hutchinson Cancer Research Center) | Phase 1 Clinical | Fred Hutchinson Cancer Research Center, National Cancer Institute | Liposarcoma; Sarcoma, Synovial; Sarcoma | Details | |
Tcrx T cell Therapy(Second Affiliated Hospital School Of Zhejiang University School Of Medicine) | Phase 1 Clinical | Second Affiliated Hospital School Of Zhejiang University School Of Medicine | Esophageal Neoplasms; Stomach Neoplasms | Details | |
SCRI-E2CAR_EGFRtv1 | SCRI-E2CAR_EGFRtv1 | Phase 1 Clinical | Umoja BioPharma Inc | Osteosarcoma | Details |
68-Ga-NODAGA-SNA-006 | SNA-006; 68-Ga-NODAGA-SNA-006 | Phase 1 Clinical | Smartnuclide Biopharma | Solid tumours | Details |
GRANITE | GRANITE-001; GRT-C901/GRT-R902 | Phase 3 Clinical | Bristol-Myers Squibb Company, Gritstone Bio Inc | Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Colonic Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
89Zr-Df-crefmirlimab | IAB-22-M2C | Phase 3 Clinical | Imaginab Inc | Solid tumours; Carcinoma, Merkel Cell; Carcinoma, Renal Cell; Multiple Sclerosis; Lymphoma; Leukoencephalopathy, Progressive Multifocal; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
RB-0003 | RB-0003; BNT-111 | Phase 2 Clinical | Biontech Se, Tron | Melanoma | Details |
GEN-009 | GEN-009 | Phase 2 Clinical | Genocea Biosciences Inc | Skin Melanoma; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung | Details |
VE-800 | VE-800 | Phase 2 Clinical | Vedanta Biosciences Inc | Esophageal Neoplasms; Stomach Neoplasms; Colorectal Neoplasms; Adenocarcinoma; Melanoma; Neoplasm Metastasis | Details |
EBViNT Cell (Eutilex) | Phase 2 Clinical | Eutilex | Lymphoma, Extranodal NK-T-Cell | Details | |
ZED88082A | ZED88082A | Phase 2 Clinical | Umcg The University Medical Center Groningen | Neoplasms; Neoplasm Metastasis | Details |
NY-ESO-1-specific autologous CD8+ T-cell therapy (Fred Hutchinson Cancer Research Center) | Phase 1 Clinical | Fred Hutchinson Cancer Research Center, National Cancer Institute | Liposarcoma; Sarcoma, Synovial; Sarcoma | Details | |
Tcrx T cell Therapy(Second Affiliated Hospital School Of Zhejiang University School Of Medicine) | Phase 1 Clinical | Second Affiliated Hospital School Of Zhejiang University School Of Medicine | Esophageal Neoplasms; Stomach Neoplasms | Details | |
SCRI-E2CAR_EGFRtv1 | SCRI-E2CAR_EGFRtv1 | Phase 1 Clinical | Umoja BioPharma Inc | Osteosarcoma | Details |
68-Ga-NODAGA-SNA-006 | SNA-006; 68-Ga-NODAGA-SNA-006 | Phase 1 Clinical | Smartnuclide Biopharma | Solid tumours | Details |
This web search service is supported by Google Inc.